The White House is set to announce on Tuesday (30) the launch of TrumpRx, a sales portal for medications aimed at the end consumer, according to information published by the Wall Street Journal. The project also includes a partnership with Pfizer, which has committed to reducing prices on some of its medicines in the United States. President Donald Trump will participate in the official announcement, accompanied by the pharmaceutical company’s CEO.
The site will allow American citizens to buy medications directly from a government-managed portal, paying cash for certain products. Prices would be reduced through negotiations conducted by the federal government itself. It is still unclear how many and which medications will be included on the platform, nor whether it will truly benefit the majority of the population, already covered by private health insurance, Medicare, or Medicaid.
The initiative represents another step by the White House in its attempt to tackle the high costs of the American pharmaceutical industry, a recurring theme in public debate that generates strong political pressure. The presence of Pfizer’s CEO at the announcement reinforces the intention to demonstrate the industry’s support for the project.
Despite the expectation around the promised discounts, health experts note that the measure may have limited impact. This is because a significant portion of consumers already has insurance coverage, which may reduce the appeal of TrumpRx as a purchasing alternative.
The official announcement will provide more details on the site’s operation and the terms and conditions agreed with Pfizer, a company that holds a prominent position in the global pharmaceutical market.
Source: www.brasil247.com